To conduct a comprehensive analysis of proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibodies based on a multi-dimensional evaluation method, providing a reference for clinical medication selection and drug selection in medical institutions.
Referring to the evaluation system in the Quick Guide for Drug Evaluation and Selection in Chinese Medical Institutions (the 2nd edition), with appropriate adjustments to some scoring criteria, a quantitative assessment was conducted on six PCSK9 monoclonal antibodies available in the domestic market from five aspects: pharmaceutical characteristics, efficacy, safety, economy, and other attributes. The recommendation grades were determined based on the scoring results.
The quantitative scoring results, ranked from high to low, were as follows: evolocumab (79.31 points), alirocumab (74.85 points), tolersimab (73.86 points), recaticimab (71.95 points), ongericimab (70.9 points), and ebronucimab (70.88 points).
All six PCSK9 monoclonal antibodies demonstrated good lipid-lowering efficacy. Among them, evolocumab, alirocumab, and tolersimab are strongly recommended, while the others are weakly recommended.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |